Abstract:Background Hepatocellular carcinoma (HCC) is one of the world’s most lethal malignant tumors with a poor prognosis. Growing evidence has been demonstrating that immune-related long non-coding RNAs (lncRNAs) are relevant to the tumor microenvironment (TME) and can help assess the effects of immunotherapy and evaluate one’s prognosis. This study aims to identify an immune-related lncRNA signature for the prospective assessment of the immunotherapy and prognosis in HCC. Method We downloaded HCC RNA-seq data and clinical information from The Cancer Genome Atlas (TCGA) project database. We first used ESTIMATE to evaluate the TME. Then, we conducted a cox regression analysis to construct a prognostic signature and the riskScore. We then applied the univariate Cox regression, multivariate Cox regression, principal components analysis (PCA), receiver operating characteristic (ROC) curve, and stratification analyses to confirm our previous assessments. Afterward, we employed a gene set enrichment analysis (GSEA) to explore the biological processes and pathways. Besides, we used CIBERSORT to estimate the abundance of tumor-infiltrating immune cells (TIICs). Furthermore, we investigated the relationship between the immune-related lncRNA signature and immune checkpoint genes. Finally, we used the quantitative real-time polymerase chain reaction (qRT-PCR) assays to demonstrate the expression of the six lncRNAs. Results We identified six immune-related lncRNAs — MSC-AS1, AC145207.5, SNHG3, AL365203.2, AL031985.3, NRAV — which show the ability to stratify patients into high-risk and low-risk groups with significantly different survival rates. The univariate Cox regression, multivariate Cox regression, ROC, and stratification analyses confirmed that the immune-related six-lncRNA signature was a novel independent prognostic factor in HCC patients. The high-risk group and low-risk group illustrated contrasting distributions in PCA. The GSEA suggested that the immune-related six-lncRNA signature was involved in the immune-related biological processes and pathways. Besides, the immune-related six-lncRNA signature was associated with the infiltration of immune cells. Furthermore, it was linked with the expression of critical immune genes and could predict immunotherapy’s clinical response. Finally, the qRT-PCR demonstrated that the six lncRNAs were significantly differentially expressed in HCC cell lines and normal hepatic cell lines. Conclusion In summary, we identified an immune-related six-lncRNA signature that can predict the outcomes, immune cell infiltration, and immunotherapy response in patients with hepatocellular carcinoma.

Identification of an Immune-Related RNA-binding Protein Signature to Predict Survival and Targeted Therapy Responses in Liver Cancer.

Identification and Validation of an Immune-Associated RNA-Binding Proteins Signature to Predict Clinical Outcomes and Therapeutic Responses in Glioma Patients.

Identification and Validation of an RNA Binding Proteins-Associated Prognostic Signature for Non-Small Cell Lung Cancer

A Novel RNA Binding Protein-Related Prognostic Signature for Hepatocellular Carcinoma

Identification of an RNA binding protein-related gene signature in hepatocellular carcinoma patients

Transcriptomic signature associated with RNA-binding proteins for survival stratification of laryngeal cancer

Signature based on RNA-binding protein-related genes for predicting prognosis and guiding therapy in non-small cell lung cancer

Identification and Experimental Validation of Immune-Associate Lncrnas for Predicting Prognosis in Cervical Cancer

Identification of biomarkers of hepatocellular carcinoma gene prognosis based on the immune-related lncRNA signature of transcriptome data

Identification of prognostic immune-related lncRNA signature predicting the overall survival for colorectal cancer

Identification of an individualized RNA binding protein‐based prognostic signature for diffuse large B‐cell lymphoma

Prognostic Value and Immunological Characteristics of a Novel RNA Binding Protein Signature in Cutaneous Melanoma

Comprehensive Characterization of RNA-Binding Proteins in Colon Adenocarcinoma Identifies a Novel Prognostic Signature for Predicting Clinical Outcomes and Immunotherapy Responses Based on Machine Learning

An immune infiltration-related long non-coding RNAs signature predicts prognosis for hepatocellular carcinoma

A novel RNA binding protein-associated prognostic model to predict overall survival in hepatocellular carcinoma patients

Integrated Bioinformatic Analysis of RNA Binding Proteins in Hepatocellular Carcinoma

Correction To: Identification of Biomarkers of Hepatocellular Carcinoma Gene Prognosis Based on the Immune‑related Lncrna Signature of Transcriptome Data

Construction of an Immune-Related Six-lncRNA Signature to Predict the Outcomes, Immune Cell Infiltration, and Immunotherapy Response in Patients With Hepatocellular Carcinoma

Identification and validation of RNA‐binding protein‐related gene signature revealed potential associations with immunosuppression and drug sensitivity in glioma

Integrated Analysis of the Functions and Prognostic Values of RNA Binding Proteins in Lung Squamous Cell Carcinoma.

Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma